# Epinastine **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/epinastine **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-03-29 **Evidence Score:** 2 / 10 **Category:** Other **Also Known As:** Epinastine hydrochloride, Elestat, WAL 801CL, (±)-3-Amino-9,13b-dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepine hydrochloride, Benzazepine antihistamine, Relestat ## Overview Epinastine is a dual-acting ophthalmic antihistamine and mast cell stabilizer that selectively antagonizes H1 histamine receptors in ocular tissue to relieve allergic conjunctivitis symptoms. It also inhibits the release of inflammatory mediators such as histamine and [prostaglandin](/ingredients/condition/inflammation)s from mast cells, providing both immediate and preventive antiallergic action. ## Health Benefits • Provides relief from allergic conjunctivitis symptoms, with high selectivity for the H1 receptor (evidence lacking specific trial data). • Does not significantly cross the blood-brain barrier, minimizing central nervous system side effects (preliminary evidence). • Inhibits histamine release from mast cells, reducing allergic reactions (evidence lacking specific trial data). • Metabolized by CYP2B6 and CYP2D6, indicating potential for minimal systemic drug interactions (evidence lacking specific trial data). • Topical use limits systemic side effects due to targeted local action in the eyes (preliminary evidence). ## Mechanism of Action Epinastine acts as a selective H1 receptor antagonist, competitively binding to histamine H1 receptors on conjunctival tissue to block histamine-mediated vasodilation, itching, and redness. It also functions as a mast cell stabilizer, inhibiting the IgE-mediated degranulation of mast cells and thereby reducing the release of histamine, [prostaglandin](/ingredients/condition/inflammation)s, and leukotrienes. Its limited permeability across the blood-brain barrier is attributed to its hydrophilic molecular structure, which restricts central nervous system receptor occupancy compared to first-generation antihistamines. ## Clinical Summary Randomized controlled trials of ophthalmic epinastine 0.05% (Elestat) have demonstrated statistically significant reductions in ocular itching scores compared to placebo in conjunctival allergen challenge models, typically enrolling 100–200 subjects. A pivotal Phase III trial found that epinastine provided relief of itching within 3 minutes of instillation and maintained efficacy for up to 8 hours post-dose. Head-to-head studies suggest comparable or slightly superior ocular itch relief versus olopatadine 0.1% in some conjunctival challenge models, though findings are not entirely consistent across trials. Overall evidence is considered moderate-quality; most trials are short-term (days to weeks) and industry-sponsored, limiting generalizability to chronic allergic disease management. ## Nutritional Profile Epinastine is a synthetic pharmaceutical compound (molecular formula: C16H15N3, molecular weight: 249.31 g/mol), not a nutritional ingredient, and therefore contains no macronutrients, micronutrients, dietary fiber, or protein in any meaningful nutritional sense. It is a second-generation antihistamine and mast cell stabilizer administered as an ophthalmic solution (0.05% w/v, equivalent to 0.5 mg/mL) or oral tablet (10–20 mg). As a small-molecule active pharmaceutical ingredient, it contains no vitamins or minerals. Its bioactive identity is defined by its dual antagonism at H1 histamine receptors (Ki approximately 1.0 nM) and additional affinity for H2, alpha-1 adrenergic, and 5-HT2 receptors at higher concentrations. Oral bioavailability is approximately 55–60%, with plasma protein binding around 64%. It is minimally metabolized (primarily via CYP enzymes, specific isoform data limited but CYP3A4 involvement suggested), with approximately 55% excreted unchanged in urine. Half-life is approximately 12 hours. Ophthalmic formulation bioavailability is low systemically due to limited transcorneal absorption. No caloric value, glycemic index, or nutrient density is applicable to this compound. ## Dosage & Preparation No clinically studied dosage ranges are specified. Epinastine is used topically as eye drops; specific dosing is not detailed. Consult a healthcare provider before starting any new supplement. ## Safety & Drug Interactions The most commonly reported adverse effects in clinical trials include transient burning or stinging upon instillation (reported in approximately 10% of users), folliculosis, hyperemia, and pruritus at the application site. Systemic absorption following ophthalmic use is minimal, making clinically significant drug-drug interactions rare; however, concurrent use with MAO inhibitors or CNS depressants should be approached cautiously given epinastine's weak affinity for alpha-adrenergic and [serotonin](/ingredients/condition/mood) receptors. Epinastine is classified as FDA Pregnancy Category C, meaning adequate human studies are lacking and it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Contact lenses should be removed prior to instillation and may be reinserted 10 minutes later, as the preservative benzalkonium chloride can adsorb onto soft lens material. ## Scientific Research The research dossier lacks detailed information on specific human clinical trials or meta-analyses for epinastine. No PMIDs or study outcomes are described, indicating a gap in comprehensive clinical evidence. ## Historical & Cultural Context Epinastine has no evidence of traditional use, as it is a fully synthetic pharmaceutical developed in modern times. There is no historical or medicinal system context for its use. ## Synergistic Combinations Cetirizine, Loratadine, Ketotifen, Cromolyn Sodium, Olopatadine ## Frequently Asked Questions ### How quickly does epinastine work for eye allergies? Epinastine 0.05% ophthalmic solution begins relieving ocular itching within approximately 3 minutes of instillation based on conjunctival allergen challenge studies. The duration of action extends up to 8 hours per dose, supporting a twice-daily dosing schedule for sustained symptom control throughout the allergy season. ### What is the difference between epinastine and olopatadine eye drops? Both epinastine and olopatadine are dual-acting H1 antagonists and mast cell stabilizers used for allergic conjunctivitis, but they differ in receptor selectivity and dosing. Olopatadine 0.1% is dosed twice daily, while olopatadine 0.2% (Pataday) is dosed once daily; epinastine 0.05% is also dosed twice daily. Some conjunctival challenge studies show comparable itch relief between the two agents, and no single drug has demonstrated definitive superiority across all clinical endpoints. ### Does epinastine cause drowsiness? Epinastine is significantly less likely to cause drowsiness compared to first-generation antihistamines like diphenhydramine because its hydrophilic structure restricts penetration across the blood-brain barrier. Systemic absorption from ophthalmic administration is also very low, further reducing the risk of CNS side effects. Clinical trials of the 0.05% eye drop formulation did not identify sedation as a notable adverse event. ### What is the correct dosage of epinastine eye drops? The standard FDA-approved dosage for epinastine hydrochloride ophthalmic solution 0.05% (Elestat) is one drop instilled into each affected eye twice daily. Treatment should continue throughout the period of allergen exposure, even when symptoms are not actively present, given epinastine's mast cell stabilizing properties that provide a preventive effect. It is indicated for patients aged 3 years and older. ### Can epinastine be used for skin allergies or only eye allergies? Epinastine is currently approved exclusively as an ophthalmic formulation for the treatment of allergic conjunctivitis; there is no approved oral or topical skin formulation in the United States. While the molecule has systemic antihistamine properties demonstrated in pharmacological studies, clinical development for systemic allergic conditions such as urticaria or rhinitis has not resulted in an approved product. Patients seeking antihistamine therapy for skin or nasal allergy symptoms should consult a physician about oral antihistamine options such as cetirizine or fexofenadine. ### Is epinastine safe for children and what age can it be used? Epinastine eye drops are generally safe for children, with studies supporting use in pediatric populations for allergic conjunctivitis. The typical recommended age is 3 years and older, though dosing should be confirmed with a healthcare provider. Safety data in infants under 3 years is limited, so a doctor's evaluation is necessary before use in very young children. ### Does epinastine interact with other eye medications or systemic drugs? Epinastine has minimal systemic absorption due to topical application to the eye, reducing the risk of significant drug interactions with oral medications. However, it should not be mixed with other eye drops without consulting a pharmacist, as some combinations may reduce efficacy or cause irritation. Patients taking oral antihistamines or decongestants should inform their eye care provider before using epinastine to ensure safe co-administration. ### What clinical evidence supports epinastine's effectiveness compared to other antihistamine eye drops? Epinastine demonstrates high selectivity for H1 receptors and rapid onset of action, making it effective for allergic conjunctivitis symptoms, though large-scale comparative trials with specific efficacy metrics are limited. Most clinical support comes from its mechanism of action—dual inhibition of histamine release and H1 receptor antagonism—rather than head-to-head studies against newer alternatives. Healthcare providers often select epinastine based on its favorable safety profile and patient tolerance rather than superior clinical trial data over competitors. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*